New hope for pancreatic cancer: experimental drug aims to keep disease in check
NCT ID NCT07344220
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called DZ-002 in adults with metastatic pancreatic cancer that has been stabilized with initial chemotherapy. The goal is to find the best dose and see if it is safe and can help keep the cancer from growing. Participants receive weekly IV infusions of DZ-002 in 4-week cycles until side effects become too severe or the disease worsens.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hoag Memorial Hospital Presbyterian
Newport Beach, California, 92663, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
- Could a vaccine help fight Hard-to-Treat cancers?
- Blood and gut clues may flag pancreatic cancer risk early
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- MRI might reveal hidden pancreatic risks in obesity
- Can a new PET tracer light up hidden cancers?